Feiba NF Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Feiba NF market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to the rising incidence of hemophilia, a shift toward prophylactic treatment, an increased focus on quality of life, and advancements in manufacturing.

Growth during the market's forecast period can be driven by increasing awareness of hemophilia management, regulatory approvals for new indications, the effectiveness in reducing bleeding episodes, the rising incidence of hemophilia cases, and market expansion into emerging economies. Key trends in the forecast period include product innovations, collaborations, and the approval of new products.

The increasing prevalence of hemophilia is expected to drive the growth of the feiba NF market in the future. Hemophilia is a rare inherited bleeding disorder where the blood does not clot properly, resulting in excessive bleeding from injuries or surgeries, as well as spontaneous internal bleeding. The rising prevalence of hemophilia is influenced by factors such as better genetic testing, heightened awareness and diagnosis, new mutations, and improved treatment options that contribute to longer life expectancy. Feiba NF helps hemophilia patients by providing an effective treatment to manage bleeding episodes and offering routine prophylaxis, reducing the frequency of these episodes and enhancing long-term disease management. This ultimately improves the patient’s quality of life and reduces the associated risks. For example, in June 2023, the National Library of Medicine, a US-based biomedical library, reported that hemophilia occurs in approximately 1 in 10,000 live births, with about 400,000 people affected worldwide. Hemophilia A is more prevalent, accounting for 80-85% of cases, affecting 1 in 5,000 live male births, while Hemophilia B affects 1 in 30,000 live male births. Hemophilia C, caused by factor XI deficiency, is rarer, occurring in around 1 in 100,000 people, with a notable incidence among Ashkenazi Jews (about 8%). Furthermore, the World Federation of Hemophilia (WFH) reported in June 2023 that as of 2022, the estimated prevalence of hemophilia A was approximately 17.1 per 100,000 males, with 6 per 100,000 for severe cases. For hemophilia B, the rates were 3.8 per 100,000 males overall and 1.1 per 100,000 for severe cases. Thus, the rising prevalence of hemophilia is fueling the growth of the feiba NF market.

The increase in healthcare expenditure is expected to further stimulate the growth of the feiba NF market. Healthcare expenditure refers to the total spending on health services and related activities over a specific period, usually annually. The rising healthcare expenditure is attributed to factors such as an aging population, the prevalence of chronic diseases, higher service prices, increased demand, technological advancements, rising drug costs, the effects of COVID-19, medical inflation, and income disparities. Healthcare expenditure directly supports feiba NF by funding the development, approval, and accessibility of advanced treatments for hemophilia patients with inhibitors, ensuring they have access to life-saving therapies that control bleeding episodes and improve long-term disease management. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that healthcare spending in the UK increased by 5.6% between 2022 and 2023, compared to a growth of just 0.9% in 2022. In 2023, the UK’s healthcare expenditure reached approximately $317.63 billion (£292 billion). Therefore, the growing healthcare expenditure is contributing to the expansion of the feiba NF market.

A key trend in the feiba NF market is the focus on technological innovations, particularly in routine prophylaxis, to reduce the frequency of bleeding episodes in hemophilia patients with inhibitors. Routine prophylaxis is a preventive approach aimed at reducing the risk of bleeding episodes through measures such as medications, vaccinations, or health screenings before medical procedures. For instance, in June 2023, Takeda Pharmaceuticals U.S.A. Inc., a US-based biopharmaceutical company, announced that FEIBA had been approved by the U.S. Food and Drug Administration (FDA) to manage bleeding episodes and provide routine prophylaxis to reduce or prevent bleeding episodes in hemophilia patients with inhibitors. This advancement enhances FEIBA's role in the long-term management of hemophilia, offering patients a more proactive approach to managing their condition. Routine prophylaxis represents a major step forward in treating hemophilia patients with inhibitors, helping to minimize the occurrence of bleeding episodes and improve their overall quality of life.

The key company operating in the feiba NF market is Takeda Pharmaceuticals Inc.

North America was the largest region in the feiba NF market in 2024. The regions covered in FEIBA NF report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the feiba NF market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

FEIBA NF (Factor VIII Inhibitor Bypassing Activity) is a plasma-derived therapy used to treat bleeding in hemophilia patients who have developed inhibitors to factors VIII or IX. It contains coagulation factors that bypass these inhibitors, promoting clotting. This medication is indicated for managing bleeding episodes and supporting surgical procedures, with close monitoring for thromboembolic risks.

The key indications for the feiba NF market include hemophilia A and B with inhibitors, prophylactic treatment, and on-demand treatment. Hemophilia A and B are inherited disorders that prevent proper blood clotting, resulting in excessive bleeding. Inhibitor patients have developed antibodies that interfere with the action of traditional clotting factor therapies. These medical treatments are distributed through various channels such as hospitals, specialty pharmacies, and direct-to-consumer methods, serving a range of end users, including both adult and pediatric patients.

The feiba NF market research report is one of a series of new reports that provides feiba NF market statistics, including feiba NF industry global market size, regional shares, competitors with a feiba NF market share, detailed feiba NF market segments, market trends and opportunities, and any further data you may need to thrive in the feiba NF industry. This feiba NF market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The feiba NF market consists of sales of FEIBA NF 500 U, 1000 U, and 2500 U, and formulations offering 350-650 U and 700-1300 U per mL designed for managing bleeding in haemophilia patients with inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.